Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating

Company Overview - Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a biotechnology company founded in 2013 and headquartered in San Diego, California, focusing on RNA medicines for rare and infectious diseases, utilizing a differentiated RNA technology platform to target large market opportunities [4] Recent Developments - Citi has lowered its price target on Arcturus from $9 to $7 while maintaining a Neutral rating, indicating a selective approach towards SMID-cap biotech as it heads into 2026, with a focus on upcoming clinical and regulatory catalysts [1] - Arcturus has initiated a first-in-human Phase 1 study for ARCT-2304, a self-amplifying mRNA-based pandemic influenza vaccine, which is seen as a significant early inflection point for the company [3] - Positive safety and immunogenicity data from the Phase 1 study could enhance Arcturus' strategic positioning, potentially leading to future partnerships, grant funding, or non-dilutive capital [3] Market Sentiment - Until clinical results are disclosed, Arcturus shares are expected to remain range-bound, with market sentiment influenced by expectations regarding data timing and management commentary [3]